

Press release from Emotra AB (publ)

Göteborg, September 10, 2015

Resolution on share issue with right of priority in Emotra AB (publ)

Yesterday, September 9, 2015, the Board of Emotra AB (publ) – following its authorisation to do so by an extraordinary shareholder meeting – decided to carry out a new share issue with right of priority. This issue is limited to a maximum of 4,326,300 shares. This new share issue is also open to the general public. If fully subscribed, this new share issue will provide Emotra with a cash injection of appr. 12.3 MSEK before issue expenses. To enable a further widening of the Company's shareholder base, the Board also intends to decide on a directed share issue (over-allocation option), to be used if the new share issue with right of priority is fully subscribed in the first step. This over-allocation option, if applied, will be carried out under the same terms and conditions as the new share issue. If the over-allocation is fully subscribed, the Company will receive a further appr. 2 MSEK. Emotra has already received subscription commitments for a total of appr. 3.1 MSEK and subscription guarantees amounting to another appr. 3.1 MSEK, which in total amounts to about 50% of the new share issue volume (excluding any over-allocation option). These guaranteed subscribers will be allocated shares in the new issue if the share issue is not fully subscribed (excluding any over-allocation option) by current shareholders and the general public. However, these guaranteed subscribers are only obligated to purchase shares for their stated guarantee amounts.

Emotra in short

Suicide is the world's fifth most common cause of death. Every year, around 1 million people take their own lives. Every day, four Swedes commit suicide, while another 20-30 people try to. Emotra has developed a method – EDOR – aimed at detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed.

Reason for the new share issue

Emotra's goal is to commence the launch of its product EDOR in late 2016/early 2017. The Company's ability to establish the EDOR method in the psychiatric community and reach a consensus about the possibilities it offers, thereby paving the way for a quick market penetration, is crucial for its ability to carry out this launch. The main goal of this new share issue is to inject capital to enable the Company to finish its clinical multi-centre study, increase its working capital, finance the development of both hardware and software as well as preparatory market activities.

Present situation

Emotra is in an initial commercialisation phase and, so far, its equipment sales have only been for research reasons. It is the Board's conviction that the EDOR method must gain market acceptance before the Company can increase its sales volume. For this reason, a clinical multi-centre study is now being carried out. This study involves 18 internationally leading psychiatric clinics across Europe. In the study, these clinics carry out their own evaluations of the EDOR method, which, if the results are promising, the Board believes will establish the method on the market and facilitate a quick market penetration.

On January 30, 2014, Emotra finalised a new share issue with right of priority that was heavily over-subscribed (250% subscription rate) and which provided the Company with appr. 9.7 MSEK, before issue expenses. The main purpose of the funds generated in that share issue was to finance the Company's clinical multi-centre study, which was planned to be carried out in collaboration with 15 European clinics, as well as the Company's day-to-day operations. Emotra's multi-centre study is ongoing and for all intents and purposes is proceeding as planned. Between mid-February and the end of March 2015, Emotra received approximately 150 tests for analysis. At present, more than 700 patients have been tested in this study. The Board estimates that the involved clinics will have tested about 1800 patients by year-end. All of these patients will be followed regarding suicide and suicide attempts for twelve months after their respective tests have been completed. The Company is presently about six months behind schedule for the following two reasons:

1. More clinics than planned are participating in the study
Initially, the Company had planned to involve 15 clinics across Europe in its clinical multi-centre study. However, due to the enormous interest to participate in it, the study was expanded from these first 15 clinics to the present 18. The study's start date was postponed to accommodate the participation of all 18 clinics. At present, 16 of the 18 clinics have received ethics committee approval, which is a requirement before any clinic is allowed to start work on the trial.
2. Previous technical problems (now resolved)
As the study got going, we encountered technical difficulties transferring EDOR test data from the clinics to Emotra. The problem has now been solved, but it delayed the start of our study. With the help of technical

experts, Emotra has now migrated to a cloud-based solution for test data. The new software was implemented in February 2015.

Overview of the terms and conditions for the new share issue

- The subscription period is September 23 – October 7, 2015.
- The subscription price is 2.85 SEK per share.
- Allocated shares must be fully paid up no later than October 7, 2015.
- The record date is September 18, 2015.
- The final day for trading in the company's shares with subscription rights is September 16, 2015, and the first day without subscription rights is September 17, 2015.
- Preferential right: Shareholders whose Emotra shares are registered on September 18, 2015 will have right of priority in the new share issue. Each outstanding share entitles the owner to one (1) subscription right. Six (6) subscription rights allow the shareholder to subscribe to five (5) new shares. Please note that this new share issue is also open to the general public.
- The offering comprises 4,326,300 new shares. If fully subscribed, this new share issue will provide the Company with a cash injection of 12,329,955 SEK before issue expenses. The number of shares before the new issue is 5,191,560.
- To further widen the Company's shareholder base, the Board also intends to decide on a directed new share issue, a so-called over-allocation option, amounting to a further maximum of 1,995,000 SEK, to be used if the new share issue with right of priority is fully subscribed in the first step.
- Emotra has received written subscription commitments for a total of appr. 3.1 MSEK and subscription guarantees amounting to appr. 3.1 MSEK, which in total constitute approximately 50% of the new share volume. These guaranteed subscribers will be allocated shares in the new issue if the share issue is not fully subscribed (excluding any over-allocation option) by current shareholders and the general public. However, these guaranteed subscribers are only obligated to purchase shares for their stated guarantee amounts.
- The pre-money value of this new share issue is appr. 14.8 MSEK.
- Trading in subscription rights will be carried out on AktieTorget during the period September 23 to October 5, 2015.
- Trading in PSS (Paid Subscribed Shares) will be carried out on AktieTorget from September 23, 2015, until the share issue has been registered at Bolagsverket. We expect this registration to be completed at the end of October 2015.
- Emotra's share is listed on AktieTorget.

Complete terms and instructions, information about subscription commitments and subscription guarantees as well as a memorandum and folder will be published on the company's web site (www.emotra.se), Sedermera Fondkommission's web site (www.sedermera.se) and AktieTorget's web site (www.aktietorget.se) no later than the commencement of the subscription period.

Financial Advisor

Emotra's Financial Advisor in connection with this new share issue is Sedermera Fondkommission.

For further information, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se